Search
Memorial Sloan Kettering Cancer Center (MSK) today announced that the New York State Department of Health has issued approval for a new molecular assay, Analysis of Circulating cfDNA to Evaluate Somatic Status (MSK-ACCESS). MSK-ACCESS was developed within the Marie-Josee and Henry R. Kravis Center for Molecular Oncology (CMO) and the test has been clinically validated and implemented by members of MSK’s Molecular Diagnostics Service.
Memorial Sloan Kettering Cancer Center (MSK) today announced that Rémy Evard has joined as its new Chief Digital Officer and Head of Technology.
Sloan Kettering Institute investigators have learned how Hedgehog proteins, which are important in both development and cancer, are assembled.
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
An MSK program helps lung cancer survivors stay healthy following successful treatment for their disease.
Un programa de MSK ayuda a los sobrevivientes de cáncer pulmonar a mantenerse saludables después de un tratamiento exitoso contra su enfermedad.
Learn how a blood test could someday provide a way to detect cancers at an early stage.
In her role as Vice Chair Health Equity, Department of Surgery, Carol Brown, MD, took part in The Atlantic’s virtual event, People v. Cancer: Equity in Care.
The majority of young women at an increased risk of breast cancer due to chest radiation treatment for childhood cancer are not following breast cancer screening recommendations, according to a recently released, detailed assessment appearing in the January 28, 2009, issue of the Journal of the American Medical Association.
On April 27 and 28 at Mohonk Mountain House in New Paltz, New York, Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) held its fifth biennial retreat for members of the school’s community.